Madrigal Pharmaceuticals
500 Office Center Drive
Suite 400
Fort Washington
Pennsylvania
19034
United States
Tel: 267-327-4445
Website: http://www.madrigalpharma.com/
Email: info@madrigalpharma.com
49 articles with Madrigal Pharmaceuticals
-
The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
-
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
6/7/2018
Madrigal Pharmaceuticals, Inc. announced the pricing of an underwritten registered public offering of 1,347,232 shares of its common stock at a public offering price of $305.00 per share.
-
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
6/5/2018
Madrigal Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $200 million of its common stock.
-
Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).
-
When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.
-
Analysts with The Motley Fool looked at three biotech stocks that even biotech-leery investors might consider.
-
MGL-3196 was well-tolerated with primarily mild and some moderate AEs.
-
A look at three small biotechs that big drugmakers are drooling over.
-
Madrigal Pharma Prices Public Offering of Common Stock
12/19/2017
Madrigal Pharma today announced the pricing of an underwritten registered public offering of 1,506,025 shares of its common stock at a public offering price of $83.00 per share.
-
Madrigal Pharma Announces Proposed Public Offering of Common Stock
12/18/2017
Madrigal Pharma today announced that it has commenced an underwritten public offering of $100M of its common stock.
-
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
-
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients With Biopsy-Proven Non-alcoholic Steatohepatitis (NASH) in Phase II Clinical Trial
12/6/2017
In this trial, MGL-3196 demonstrated statistically significant results for the primary endpoint.
-
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results
11/9/2017
Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively.
-
Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver Meeting
10/23/2017
Results demonstrate that mgl-3196 provides metabolic, anti-inflammatory and anti-fibrotic benefits in a long-term, high fat diet, mouse NASH model.
-
Madrigal Announces Positive Outcome From Pre-Planned DSMB Safety Review And Completion Of Enrollment Of Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia
9/19/2017
-
Madrigal Reports 2017 Second Quarter Financial Results
8/10/2017
-
Madrigal Completes Enrollment In Phase II Proof-Of-Concept Study With MGL-3196 For Treatment Of NASH
8/1/2017
-
Madrigal Announces $35 Million Private Placement Offering
6/21/2017
-
Madrigal Reports 2017 First Quarter Financial Results
5/12/2017
-
Madrigal Reports 2016 Fourth Quarter And Year-End Financial Results, Reviews Key Corporate Achievements And Provides Update On Lead Clinical-Stage Compound, MGL-3196
4/3/2017